Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived medicines with a track record of more than 100...
Grifols, S.A. ("Grifols") (MCE: GRF), (MCE: GRF.P) and (NASDAQ: GRFS) announced that it has filed its 2020 Annual Report on Form 20-F with the United ...
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and leader in the development of...
Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for...
Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and one of the world's leading producers of plasma-derived medicines with ...
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of...
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative...
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and one of world's top producers of plasma-derived medicines, today...
Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, today announced the launch of a new 3-mL (900-IU)...
Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company with a track record of more than 100 years and a recognized leader in the...
Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for...
Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, today announced the launch of its latest...
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines, today concluded more than a year of encouraging...
Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for...
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines, will present the final and complete clinical,...
Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative...
A Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), uma produtora líder global de medicamentos derivados do plasma e soluções para transfusão, anunciou ...
The Grifols Clinical Research team, led by Dr. Antonio Páez, today presented additional results of its AMBAR (Alzheimer Management by Albumin...
Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ: GRFS), a leading global producer of plasma-derived medicines, announced today that Xembify®, its new 20%...
Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening...
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases,...
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for...
Grifols is pleased to announce the opening of a new Biotest plasma donor center located at 108 West Hendry Street, Hinesville, Georgia. The 11,000...
Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that its U.S. network ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.